SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.
(Nasdaq: OPTR) today announced the presentation of results from its second
prulifloxacin Phase 3 clinical study for the treatment of infectious diarrhea
in travelers, by clinical investigator Robert Steffen, M.D., at the annual
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in
San Francisco.
